Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Picard Medical Inc. (NYSE: PMI)

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements and a pump-and-dump scheme that affected the company's stock price during a specified period [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., asserting claims on behalf of all individuals and entities who purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025 [1]. - The lead plaintiff deadline for this action is set for April 13, 2026, and individuals wishing to serve as lead plaintiff must file a motion by this date [2][7]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [4]. - It is claimed that the defendants orchestrated a pump-and-dump scheme, where the stock price was artificially inflated through a social media promotion scheme involving impersonators posing as legitimate financial advisors [4]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, production, supply, marketing, and sale of medical device products, with its most significant product being an artificial heart called "SynCardia TAH" [3]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [3].